Stock Watch: The Stubborn Hurdle Of Chronic Hepatitis B
GSK Emerges As A Contender As Others Struggle
Executive Summary
Most of the money raised by biotech companies to address chronic hepatitis B has resulted in failed programs. But wait, a glimmer of light from yonder pharma breaks.